Related Experiment Videos
MicroRNA-100 suppresses human osteosarcoma cell proliferation and chemo-resistance via ZNRF2
Qiang Xiao1, Yu Yang1, Qing An1
1Department of Hand Surgery, The First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, China.
Abstract:
Osteosarcoma (OS) is a prevalent cancer worldwide. MicroRNAs (miRNAs) play critical roles in the growth, invasion and carcinogenesis of OS, whereas the underlying mechanisms remain ill-defined. Here, we addressed these questions. We detected significantly higher levels of ZNRF2, a ubiquitin ligase of the RING superfamily, and significantly lower levels of miR-100 in the OS specimens, compared to the paired normal bone tissues. The levels of ZNRF2 and miR-100 inversely correlated in the OS specimens. In addition, low miR-100 levels are associated with poor prognosis of the OS patients. Either ZNRF2 overexpression or miR-100 depletion increased in vitro OS cell growth and improved cell survival at the presence of Doxorubicin. Mechanistically, with the help of bioinformatics analysis and luciferase-reporter assay, we found that miR-100 might bind to the 3'-UTR of ZNRF2 mRNA to prevent its protein translation. Thus, our data suggest that re-expression of miR-100 may inhibit OS cell growth and decrease OS cell chemo-resistance.
Insights
MicroRNAs (miRNAs) like miR-100 are crucial in osteosarcoma (OS) development. Lower miR-100 levels correlate with poor prognosis and increased chemo-resistance in OS patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Osteosarcoma (OS) is a common bone cancer globally.
- MicroRNAs (miRNAs) are implicated in OS progression, but mechanisms are unclear.
- ZNRF2 and miR-100 roles in OS require further investigation.
Purpose of the Study:
- To investigate the roles of ZNRF2 and miR-100 in osteosarcoma.
- To elucidate the relationship between ZNRF2, miR-100, and OS progression.
- To explore the potential of miR-100 as a therapeutic target in OS.
Main Methods:
- Comparative analysis of ZNRF2 and miR-100 levels in OS tissues versus normal bone.
- Correlation analysis between ZNRF2 and miR-100 expression and patient prognosis.
- In vitro studies on OS cell growth, survival, and chemo-resistance.
- Bioinformatics analysis and luciferase-reporter assays to confirm molecular interactions.
Main Results:
- ZNRF2 levels were significantly higher, while miR-100 levels were significantly lower in OS tissues.
- ZNRF2 and miR-100 levels showed an inverse correlation in OS specimens.
- Low miR-100 expression correlated with poor patient prognosis.
- ZNRF2 overexpression or miR-100 depletion enhanced OS cell growth and chemo-resistance.
- miR-100 directly targets ZNRF2 mRNA, inhibiting its translation.
Conclusions:
- miR-100 acts as a tumor suppressor in osteosarcoma by targeting ZNRF2.
- Restoring miR-100 levels may inhibit OS cell growth and overcome chemo-resistance.
- Targeting the miR-100/ZNRF2 axis presents a potential therapeutic strategy for osteosarcoma.